# A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors

> **NCT06932952** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Byondis B.V.** · enrollment: 7 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** BYON4228 + Pembrolizumab

## Key facts

- **NCT ID:** NCT06932952
- **Lead sponsor:** Byondis B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-07
- **Primary completion:** 2026-04
- **Final completion:** 2026-12
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06932952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06932952, "A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06932952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*